MX2015012441A - Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina. - Google Patents

Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina.

Info

Publication number
MX2015012441A
MX2015012441A MX2015012441A MX2015012441A MX2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A
Authority
MX
Mexico
Prior art keywords
heparin
monoclonal antibodies
antibodies against
complexed
antibodies
Prior art date
Application number
MX2015012441A
Other languages
English (en)
Spanish (es)
Inventor
Hermiston Terry
E Murphy John
Jin Ye
Myles Timothy
Dittmer Frank
Strerath Michael
Gritzan Uwe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015012441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2015012441A publication Critical patent/MX2015012441A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015012441A 2013-03-14 2014-03-14 Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina. MX2015012441A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784590P 2013-03-14 2013-03-14
PCT/US2014/029541 WO2014153195A1 (en) 2013-03-14 2014-03-14 Monoclonal antibodies against antithrombin beta complexed with heparin

Publications (1)

Publication Number Publication Date
MX2015012441A true MX2015012441A (es) 2016-08-08

Family

ID=50680168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012441A MX2015012441A (es) 2013-03-14 2014-03-14 Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina.

Country Status (18)

Country Link
US (4) US20140271660A1 (enExample)
EP (1) EP2970500A1 (enExample)
JP (1) JP2016519081A (enExample)
KR (1) KR20150127202A (enExample)
CN (1) CN105229033B (enExample)
AR (1) AR095499A1 (enExample)
AU (1) AU2014236198A1 (enExample)
BR (1) BR112015021399A2 (enExample)
CA (1) CA2916421A1 (enExample)
HK (1) HK1215261A1 (enExample)
MX (1) MX2015012441A (enExample)
PE (1) PE20160533A1 (enExample)
RU (1) RU2015143696A (enExample)
SG (1) SG11201506886TA (enExample)
TW (1) TW201529602A (enExample)
UY (1) UY35457A (enExample)
WO (1) WO2014153195A1 (enExample)
ZA (1) ZA201507628B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271660A1 (en) 2013-03-14 2014-09-18 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta
EP3146759B1 (en) * 2014-05-19 2021-04-07 Nokia Solutions and Networks Oy Re-establishment procedure in dual connectivity networks
EP4074730A1 (en) 2015-06-24 2022-10-19 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AR106230A1 (es) 2015-10-02 2017-12-27 Hoffmann La Roche Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
WO2017158176A1 (en) * 2016-03-18 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578253A (en) 1978-12-11 1980-06-12 Teikoku Hormone Mfg Co Ltd Immune measurement of hito antithrombin 3
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
BE896543A (fr) 1983-04-22 1983-08-16 Wallone Region Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang
JPH0644876B2 (ja) 1985-12-13 1994-06-15 株式会社ヤトロン 抗トロンビン・アンチトロンビン3複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン3複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン3複合体の精製方法
JPH0266458A (ja) 1988-09-01 1990-03-06 Takara Shuzo Co Ltd ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン3複合体の測定方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU628960B2 (en) 1989-04-07 1992-09-24 Teijin Limited Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JPH0694713A (ja) 1991-07-31 1994-04-08 Masashi Funayama アンチトロンビンiii活性の測定方法とそれを用いたアンチトロンビンiii活性の測定キット
JPH07238099A (ja) * 1994-02-25 1995-09-12 Dai Ichi Pure Chem Co Ltd モノクローナル抗体及びこれを用いる免疫学的測定法
FR2718849B1 (fr) 1994-04-14 1996-06-14 Pasteur Sanofi Diagnostics Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JP3841364B2 (ja) 1994-10-18 2006-11-01 株式会社三菱化学ヤトロン 抗ヒトビトロネクチン・トロンビン・アンチトロンビンiii 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法
DK0912738T3 (da) 1996-05-22 2008-11-17 Viventia Biotech Inc Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere
EP0912728A1 (en) 1996-05-31 1999-05-06 MediGene Aktiengesellschaft Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
ES2299425T3 (es) 1999-05-13 2008-06-01 Gtc Biotherapeutics, Inc. Antitrombina iii producida geneticamente y formas mutantes de la misma.
JP2001321167A (ja) 2000-05-10 2001-11-20 Cosmo Research Inst モノクローナル抗体
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
JP2002316999A (ja) 2001-04-17 2002-10-31 Dai Ichi Pure Chem Co Ltd モノクローナル抗体
US20090226429A1 (en) 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
WO2005016236A2 (en) 2003-05-06 2005-02-24 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2003089575A2 (en) 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
EP1530629B1 (en) 2002-05-31 2011-08-31 The University of Utah Research Foundation Variants of antithrombin iii
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
RU2262109C2 (ru) 2002-12-30 2005-10-10 Институт биохимической физики им. Н.М. Эмануэля Российской академии наук Способ определения концентрации антитромбина iii в плазме крови
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
EP1692184B1 (en) 2003-11-07 2012-03-07 Immunex Corporation Antibodies that bind interleukin-4 receptor
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
JP4942664B2 (ja) 2005-02-01 2012-05-30 モーフォシス アーゲー 抗体を単離するためのライブラリおよび方法
WO2009013251A1 (en) 2007-07-20 2009-01-29 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
PT2220221E (pt) 2007-11-29 2015-04-16 Grifols Therapeutics Inc Plasmina modificada de forma recombinante
ES2346618B1 (es) 2008-08-14 2011-08-03 Universidad De Murcia Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos.
NO330078B1 (no) 2008-09-22 2011-02-14 Optipro As Fremgangsmåte og apparat for å overvåke slitasje i sikteduker
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP3401333B1 (en) 2010-09-09 2021-05-19 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140356377A1 (en) 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
JP6095678B2 (ja) 2011-11-11 2017-03-15 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド 薬剤パッケージ用の不動態化、pH保護又は滑性皮膜、被覆プロセス及び装置
US20140271660A1 (en) * 2013-03-14 2014-09-18 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta
JP6094713B1 (ja) 2016-06-30 2017-03-15 富士ゼロックス株式会社 定着部材、定着装置、及び画像形成装置

Also Published As

Publication number Publication date
US20180244799A1 (en) 2018-08-30
US20140271660A1 (en) 2014-09-18
HK1215261A1 (zh) 2016-08-19
US9593166B2 (en) 2017-03-14
US9908942B2 (en) 2018-03-06
JP2016519081A (ja) 2016-06-30
US20140271661A1 (en) 2014-09-18
BR112015021399A2 (pt) 2017-07-18
ZA201507628B (en) 2017-11-29
RU2015143696A (ru) 2017-04-19
US20160024222A1 (en) 2016-01-28
KR20150127202A (ko) 2015-11-16
AU2014236198A1 (en) 2015-10-15
US10144784B2 (en) 2018-12-04
CA2916421A1 (en) 2014-09-25
TW201529602A (zh) 2015-08-01
EP2970500A1 (en) 2016-01-20
PE20160533A1 (es) 2016-06-09
CN105229033A (zh) 2016-01-06
AR095499A1 (es) 2015-10-21
UY35457A (es) 2014-10-31
WO2014153195A1 (en) 2014-09-25
SG11201506886TA (en) 2015-09-29
CN105229033B (zh) 2019-04-23

Similar Documents

Publication Publication Date Title
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
PH12016500943A1 (en) Aplnr modulatros and uses thereof
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
MX382398B (es) Proteinas de union a antigeno st2.
WO2014164959A3 (en) Anti-il-33 antibodies and uses thereof
MX369148B (es) Agentes de unión kir3dl2.
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
JO3798B1 (ar) الأجسام المضادة ملزمة على وجه التحديد pd-1 واستخداماتها
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
MA34004B1 (fr) Protéines de liaison à cd127
WO2019121906A9 (en) Fc binding fragments comprising a pd-l1 antigen-binding site
EA201890143A3 (ru) Антитела против pdgfr-бета и их применения
MX2015012441A (es) Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina.
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
WO2014194274A3 (en) Oncostatin m receptor antigen binding proteins
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
BR112015012414A2 (pt) anticorpos monoclonais contra proteína c ativada (apc)
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
WO2013149219A3 (en) Fully human antibodies that bind to vegfr2
UA112521C2 (uk) Антитіло проти gdf8 людини
WO2014144616A3 (en) Anti-alpha v beta 5 antibodies and uses thereof